Journal ArticleOPEN ACCESS

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

  • Tewari K
  • Monk B
  • Vergote I
  • et al.
Annals of Oncology (2021) 32(7) 940-941
DOI: 10.1016/j.annonc.2021.04.009
N/ACitations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Tewari, K. S., Monk, B. J., Vergote, I., Miller, A., de Melo, A. C., Kim, H. S., … Oaknin, A. (2021). VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma. Annals of Oncology, 32(7), 940–941. https://doi.org/10.1016/j.annonc.2021.04.009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free